Biosimilar Testing Services Market Report 2026

Biosimilar Testing Services Market Overview

• Biosimilar Testing Services market size has reached to $1.84 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Growing Prevalence Of Autoimmune Diseases Is Fueling The Growth Of The Market Due To Increasing Demand For Effective And Affordable Biologic Therapies • Market Trend: Strategic Facility Expansion Driving Technological Advancements And Operational Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biosimilar Testing Services Market?

Biosimilar testing services refer to the scientific processes and analytical evaluations conducted to determine the similarity between a biosimilar and its reference biological product. These services involve a comprehensive assessment of various attributes, including structural, functional, and biological characteristics, to ensure consistency, quality, and safety. The goal is to confirm that the biosimilar matches the reference product in terms of efficacy and immunogenicity, while adhering to regulatory standards. The main service types of biosimilar testing services are analytical testing, bioanalytical testing, stability testing, method development and validation, and others. Analytical testing refers to a comprehensive set of laboratory techniques used to assess the structural and functional similarity between biosimilars and reference biologics, ensuring product quality, safety, and efficacy. It uses multiple technologies such as cell-based assays, chromatography techniques, mass spectrometry, and bioassays, and different molecule types include monoclonal antibodies, recombinant hormones, insulin, interferons, enzymes, and others. The various applications involved are oncology, autoimmune diseases, blood disorders, growth hormone deficiency, and others, and they are used by several end users such as pharmaceutical companies, biotechnology companies, contract research organizations, academic research institutes, and government agencies.

What Is The Biosimilar Testing Services Market Growth Forecast?

The biosimilar testing services market size is expected to see rapid growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growing demand for cost-effective biologic alternatives, expansion of global biosimilar markets, increasing complexity of biologic molecules, rising focus on comparability studies, growing investments in biosimilar R&D. Major trends in the forecast period include increasing demand for comprehensive analytical characterization, rising adoption of advanced bioanalytical assays, growing emphasis on regulatory-compliant testing services, expansion of outsourced biosimilar development support, enhanced focus on method validation and consistency.

Global Biosimilar Testing Services Market Segmentation

1) By Service Type: Analytical Testing, Bioanalytical Testing, Stability Testing, Method Development And Validation, Other Service Types 2) By Technology: Cell-Based Assays, Chromatography Techniques, Mass Spectrometry, Bioassays 3) By Molecule Type: Monoclonal Antibodies, Recombinant Hormones, Insulin, Interferons, Enzymes, Other Molecule Types 4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications 5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Government Agencies Subsegments: 1) By Analytical Testing: Protein Characterization, Impurity Profiling, Potency Testing, Glycosylation Analysis, Structural Analysis 2) By Bioanalytical Testing: Pharmacokinetics Analysis, Immunogenicity Testing, Biomarker Analysis, Drug Concentration Measurement, Toxicokinetics Testing 3) By Stability Testing: Long-Term Stability Testing, Accelerated Stability Testing, Stress Testing, Photostability Testing, Temperature Cycling Studies 4) By Method Development And Validation: Analytical Method Development, Bioanalytical Method Development, Method Validation, Process Validation, Assay Development 5) By Other Service Types: Immunogenicity Assessment, Formulation Development, Microbial Testing, Release Testing, Regulatory Consulting

What Is The Driver Of The Biosimilar Testing Services Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the biosimilar testing services market going forward. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues, leading to inflammation and tissue damage. The growing prevalence of autoimmune diseases is due to the increasing need for effective biologic treatments that can manage chronic symptoms, reduce flare-ups, and improve long-term patient outcomes. Biosimilar testing services support the treatment of autoimmune diseases by ensuring biosimilars are safe, effective, and comparable to original biologics, helping to provide affordable and accessible therapeutic options. For instance, in February 2024, according to the Arthritis Australia, an Australia-based non-profit organization, it is estimated that 562,378 Australians will be living with RA in 2025, accounting for 14% of all arthritis cases that year. By 2040, this number is projected to rise by 33% to 748,721 people. This represents an increase of 186,343 Australians with RA compared with 2025. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the biosimilar testing services industry.

Key Players In The Global Biosimilar Testing Services Market

Major companies operating in the biosimilar testing services market are Thermo Fisher Scientific Inc., IQVIA Laboratories, Laboratory Corporation of America Holdings, Eurofins Scientific SE, SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd., Intertek Group plc, Samsung Biologics Co. Ltd., Almac Group Limited, Syngene International Limited, Shanghai Medicilon Inc., Kymos Group S.L., Pacific BioLabs Inc., Profacgen Inc., ExcellGene SA, BioPharmaSpec Ltd., Charles River Laboratories International Inc., Covance Inc., PPD Inc., ICON plc, Parexel International Corporation, Frontage Laboratories Inc.

Global Biosimilar Testing Services Market Trends and Insights

Major companies operating in the biosimilar testing services market are focusing on expanding facilities to introduce new technologies or capabilities that enhance productivity and competitiveness. Facility expansion is the process of enlarging or upgrading an existing physical space or infrastructure to accommodate increased operational needs or future growth. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based biotechnology company, launched Tanvex CDMO, a state-of-the-art contract development and manufacturing organization located in San Diego, offering end-to-end biologics development and manufacturing services, including cell line development, process optimization, analytical testing, and regulatory support. This new facility aims to accelerate the advancement of biopharmaceutical products from concept to commercial scale, leveraging cutting-edge technologies and experienced teams to deliver innovative and life-changing biologics to patients worldwide.

What Are Latest Mergers And Acquisitions In The Biosimilar Testing Services Market?

In September 2023, Cerba HealthCare SA, a France-based clinical trial laboratory and diagnostics provider, acquired Cirion Biopharma Inc. for an undisclosed amount. Through this acquisition, Cerba HealthCare SA aims to expand its bioanalytical capabilities in biosimilars and biologics development, strengthen its North American presence, and enhance PK/PD and immunogenicity testing for complex clinical trials. Cirion Biopharma Inc. is a Canada-based contract research organization providing bioanalytical services, PK/PD and immunogenicity testing, specimen management, and R&D support from preclinical discovery through phase IV trials.

Regional Outlook

North America was the largest region in the biosimilar testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biosimilar Testing Services Market?

The biosimilar testing services market consists of revenues earned by entities by providing services such as comparability testing, structural characterization, functional characterization, impurity profiling, glycosylation analysis, pharmacokinetic studies, immunogenicity assessment, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. The biosimilar testing services market also includes sales of reference biologics, biosimilar candidates, assay kits, analytical reagents, detection reagents, and bioanalytical instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biosimilar Testing Services Market Report 2026?

The biosimilar testing services market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar testing services industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.